$16.20
0.412.60%
At Close: -
$16.20
00.00%
After Hours: 4:00 PM EDT
15 minutes delayed
Comments
Loading...
UroGen Pharma
URGNNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
UroGen Pharma (NASDAQ:URGN) Stock, Analyst Ratings, Price Targets, Forecasts
UroGen Pharma Ltd has a consensus price target of $33.58 based on the ratings of 6 analysts. The high is $60 issued by HC Wainwright & Co. on July 1, 2024. The low is $10 issued by Jefferies on February 8, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Ladenburg Thalmann, and Oppenheimer on July 1, 2024, June 14, 2024, and June 14, 2024, respectively. With an average price target of $51.17 between HC Wainwright & Co., Ladenburg Thalmann, and Oppenheimer, there's an implied 215.84% upside for UroGen Pharma Ltd from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Ladenburg Thalmann
Oppenheimer
Goldman Sachs
Jefferies
1calculated from analyst ratings
Analyst Ratings for UroGen Pharma
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/01/2024 | Buy Now | 270.37% | HC Wainwright & Co. | Raghuram Selvaraju | $60 → $60 | Reiterates | Buy → Buy | Get Alert |
| 06/14/2024 | Buy Now | 230.25% | Ladenburg Thalmann | Matthew Kaplan | $48 → $53.5 | Maintains | Buy | Get Alert |
| 06/14/2024 | Buy Now | 146.91% | Oppenheimer | Leland Gershell | $32 → $40 | Maintains | Outperform | Get Alert |
| 06/14/2024 | Buy Now | 270.37% | HC Wainwright & Co. | Raghuram Selvaraju | $54 → $60 | Maintains | Buy | Get Alert |
| 05/14/2024 | Buy Now | 233.33% | HC Wainwright & Co. | Raghuram Selvaraju | → $54 | Reiterates | Buy → Buy | Get Alert |
| 05/14/2024 | Buy Now | 97.53% | Oppenheimer | Leland Gershell | $34 → $32 | Maintains | Outperform | Get Alert |
| 05/06/2024 | Buy Now | 233.33% | HC Wainwright & Co. | Raghuram Selvaraju | → $54 | Reiterates | Buy → Buy | Get Alert |
| 04/18/2024 | Buy Now | 233.33% | HC Wainwright & Co. | Raghuram Selvaraju | → $54 | Reiterates | Buy → Buy | Get Alert |
| 04/04/2024 | Buy Now | 233.33% | HC Wainwright & Co. | Raghuram Selvaraju | → $54 | Reiterates | Buy → Buy | Get Alert |
| 03/18/2024 | Buy Now | 233.33% | HC Wainwright & Co. | Raghuram Selvaraju | → $54 | Reiterates | Buy → Buy | Get Alert |
| 03/15/2024 | Buy Now | 109.88% | Oppenheimer | Leland Gershell | $35 → $34 | Maintains | Outperform | Get Alert |
| 11/15/2023 | Buy Now | 97.53% | Oppenheimer | Leland Gershell | $33 → $32 | Maintains | Outperform | Get Alert |
| 10/04/2023 | Buy Now | 233.33% | HC Wainwright & Co. | Raghuram Selvaraju | → $54 | Reiterates | Buy → Buy | Get Alert |
| 08/14/2023 | Buy Now | 233.33% | HC Wainwright & Co. | Raghuram Selvaraju | → $54 | Reiterates | Buy → Buy | Get Alert |
| 08/01/2023 | Buy Now | 233.33% | HC Wainwright & Co. | Raghuram Selvaraju | $23 → $54 | Maintains | Buy | Get Alert |
| 07/31/2023 | Buy Now | 11.11% | Goldman Sachs | Paul Choi | $11 → $18 | Maintains | Neutral | Get Alert |
| 06/21/2023 | Buy Now | 41.98% | HC Wainwright & Co. | Raghuram Selvaraju | → $23 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | 35.8% | Oppenheimer | Leland Gershell | → $22 | Reiterates | Outperform → Outperform | Get Alert |
| 05/15/2023 | Buy Now | 41.98% | HC Wainwright & Co. | Raghuram Selvaraju | → $23 | Reiterates | Buy → Buy | Get Alert |
| 05/02/2023 | Buy Now | 41.98% | HC Wainwright & Co. | Raghuram Selvaraju | → $23 | Reiterates | → Buy | Get Alert |
| 04/10/2023 | Buy Now | 41.98% | HC Wainwright & Co. | Raghuram Selvaraju | → $23 | Reiterates | → Buy | Get Alert |
| 02/16/2023 | Buy Now | 41.98% | HC Wainwright & Co. | Raghuram Selvaraju | → $23 | Reiterates | → Buy | Get Alert |
| 02/08/2023 | Buy Now | -38.27% | Jefferies | Chris Howerton | $35 → $10 | Downgrade | Buy → Hold | Get Alert |
| 12/12/2022 | Buy Now | 41.98% | HC Wainwright & Co. | Raghuram Selvaraju | $26 → $23 | Maintains | Buy | Get Alert |
| 04/27/2022 | Buy Now | 23.46% | Berenberg | Anita Dushyanth | → $20 | Initiates | → Buy | Get Alert |
| 03/22/2022 | Buy Now | -32.1% | Goldman Sachs | Paul Choi | $10 → $11 | Maintains | Neutral | Get Alert |
| 01/18/2022 | Buy Now | 109.88% | HC Wainwright & Co. | Raghuram Selvaraju | $50 → $34 | Maintains | Buy | Get Alert |
FAQ
What is the target price for UroGen Pharma (URGN) stock?
The latest price target for UroGen Pharma (NASDAQ:URGN) was reported by HC Wainwright & Co. on July 1, 2024. The analyst firm set a price target for $60.00 expecting URGN to rise to within 12 months (a possible 270.37% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for UroGen Pharma (URGN)?
The latest analyst rating for UroGen Pharma (NASDAQ:URGN) was provided by HC Wainwright & Co., and UroGen Pharma reiterated their buy rating.
When was the last upgrade for UroGen Pharma (URGN)?
There is no last upgrade for UroGen Pharma
When was the last downgrade for UroGen Pharma (URGN)?
The last downgrade for UroGen Pharma Ltd happened on February 8, 2023 when Jefferies changed their price target from $35 to $10 for UroGen Pharma Ltd.
When is the next analyst rating going to be posted or updated for UroGen Pharma (URGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of UroGen Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for UroGen Pharma was filed on July 1, 2024 so you should expect the next rating to be made available sometime around July 1, 2025.
Is the Analyst Rating UroGen Pharma (URGN) correct?
While ratings are subjective and will change, the latest UroGen Pharma (URGN) rating was a reiterated with a price target of $60.00 to $60.00. The current price UroGen Pharma (URGN) is trading at is $16.20, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.